258 related articles for article (PubMed ID: 22934582)
21. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia.
Kovacs JA; Gill VJ; Meshnick S; Masur H
JAMA; 2001 Nov; 286(19):2450-60. PubMed ID: 11712941
[TBL] [Abstract][Full Text] [Related]
22. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study.
Helweg-Larsen J; Benfield T; Atzori C; Miller RF
J Antimicrob Chemother; 2009 Dec; 64(6):1282-90. PubMed ID: 19858161
[TBL] [Abstract][Full Text] [Related]
23. Evidence for DNA synthesis in Pneumocystis carinii trophozoites treated with the beta-1,3-glucan synthesis inhibitor pneumocandin L-693,989.
Wyder MA; Johnston LQ; Kaneshiro ES
J Eukaryot Microbiol; 2010; 57(5):447-8. PubMed ID: 20738464
[TBL] [Abstract][Full Text] [Related]
24. Use of semiquantitative PCR to assess onset and treatment of Pneumocystis carinii infection in rat model.
O'Leary TJ; Tsai MM; Wright CF; Cushion MT
J Clin Microbiol; 1995 Mar; 33(3):718-24. PubMed ID: 7751383
[TBL] [Abstract][Full Text] [Related]
25. Pneumocystis carinii exhibits a conserved meiotic control pathway.
Burgess JW; Kottom TJ; Limper AH
Infect Immun; 2008 Jan; 76(1):417-25. PubMed ID: 17984205
[TBL] [Abstract][Full Text] [Related]
26. Retracing the evolution of
Cissé OH; Ma L; Kovacs JA
Microbiol Mol Biol Rev; 2024 Jun; 88(2):e0020222. PubMed ID: 38587383
[TBL] [Abstract][Full Text] [Related]
27. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.
Hughes W; Leoung G; Kramer F; Bozzette SA; Safrin S; Frame P; Clumeck N; Masur H; Lancaster D; Chan C
N Engl J Med; 1993 May; 328(21):1521-7. PubMed ID: 8479489
[TBL] [Abstract][Full Text] [Related]
28. Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P. carinii life cycle with 1,3-beta-glucan synthesis inhibitor L-671,329.
Schmatz DM; Powles M; McFadden DC; Pittarelli LA; Liberator PA; Anderson JW
J Protozool; 1991; 38(6):151S-153S. PubMed ID: 1818147
[TBL] [Abstract][Full Text] [Related]
29. Ubiquinone synthesis and its regulation in Pneumocystis carinii.
Kaneshiro ES; Basselin M; Merali S; Kayser O
J Eukaryot Microbiol; 2006; 53(6):435-44. PubMed ID: 17123407
[TBL] [Abstract][Full Text] [Related]
30. Analogs of pentamidine as potential anti-Pneumocystis chemotherapeutics.
Maciejewska D; Zabinski J; Kaźmierczak P; Rezler M; Krassowska-Świebocka B; Collins MS; Cushion MT
Eur J Med Chem; 2012 Feb; 48():164-73. PubMed ID: 22200403
[TBL] [Abstract][Full Text] [Related]
31. Functional Characterization of Pneumocystis carinii Inositol Transporter 1.
Cushion MT; Collins MS; Sesterhenn T; Porollo A; Vadukoot AK; Merino EJ
mBio; 2016 Dec; 7(6):. PubMed ID: 27965450
[TBL] [Abstract][Full Text] [Related]
32. [Presence of Pneumocystis carinii and Pneumocystis wakefieldiae DNA in the extrapulmonary tissues of immunocompromised laboratory rats].
Gołab E
Wiad Parazytol; 2009; 55(2):167-71. PubMed ID: 19670532
[TBL] [Abstract][Full Text] [Related]
33. Pneumocystis carinii infection: current treatment and prevention.
Miller RF; Le Noury J; Corbett EL; Felton JM; De Cock KM
J Antimicrob Chemother; 1996 May; 37 Suppl B():33-53. PubMed ID: 8818828
[TBL] [Abstract][Full Text] [Related]
34. Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance.
Huang L; Crothers K; Atzori C; Benfield T; Miller R; Rabodonirina M; Helweg-Larsen J
Emerg Infect Dis; 2004 Oct; 10(10):1721-8. PubMed ID: 15504256
[TBL] [Abstract][Full Text] [Related]
35. [New aspects of epidemiology and treatment of Pneumocystis carinii infection].
Powierska-Czarny J; Gospodarek E; Czerwionka-Szaflarska M
Pol Merkur Lekarski; 2004 Nov; 17(101):534-7. PubMed ID: 15754652
[TBL] [Abstract][Full Text] [Related]
36. Comparative genomics suggests that the human pathogenic fungus Pneumocystis jirovecii acquired obligate biotrophy through gene loss.
Cissé OH; Pagni M; Hauser PM
Genome Biol Evol; 2014 Jul; 6(8):1938-48. PubMed ID: 25062922
[TBL] [Abstract][Full Text] [Related]
37. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y
J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257
[TBL] [Abstract][Full Text] [Related]
38. Pneumocystis carinii: genetic diversity and cell biology.
Smulian AG
Fungal Genet Biol; 2001 Dec; 34(3):145-54. PubMed ID: 11728153
[TBL] [Abstract][Full Text] [Related]
39. Pneumocystis jirovecii.
Nevez G; Hauser PM; Le Gal S
Trends Microbiol; 2020 Dec; 28(12):1034-1035. PubMed ID: 33171104
[No Abstract] [Full Text] [Related]
40. Failure of low-dose atovaquone prophylaxis against Pneumocystis jiroveci infection in transplant recipients.
Rodriguez M; Sifri CD; Fishman JA
Clin Infect Dis; 2004 Apr; 38(8):e76-8. PubMed ID: 15095235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
